Financial Performance - The company's operating revenue for Q1 2023 was CNY 226.19 million, a decrease of 34.96% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 28.91 million, down 69.58% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 23.39 million, a decline of 74.75% compared to the previous year[5]. - Basic and diluted earnings per share were both CNY 0.26, reflecting a drop of 69.49%[6]. - Total operating revenue for Q1 2023 was ¥226,188,708.14, a decrease of 34.9% compared to ¥347,749,231.30 in Q1 2022[26]. - Net profit for Q1 2023 was ¥28,912,951.01, a decline of 69.6% from ¥95,054,252.06 in Q1 2022[27]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.26, compared to ¥0.84 in Q1 2022[28]. - Other comprehensive income for Q1 2023 showed a loss of ¥3,395,572.09, compared to a loss of ¥57,908.67 in Q1 2022[27]. Cash Flow and Assets - The net cash flow from operating activities was CNY 37.98 million, a decrease of 27.49% year-on-year[6]. - The company's cash and cash equivalents decreased to RMB 473,557,383.16 from RMB 753,233,997.85, a reduction of approximately 37%[23]. - The cash inflow from financing activities was CNY 990,795.00, compared to CNY 661,888.80 in Q1 2022[31]. - The net cash flow from financing activities was -CNY 328,906.20, a decline from CNY 661,888.80 in the previous year[31]. - The company reported a significant decrease in cash received from sales, totaling CNY 247,885,817.43, down 38.0% from CNY 401,122,062.90 in Q1 2022[30]. - The cash outflow for purchasing goods and services was CNY 108,233,245.15, a decrease of 59.0% compared to CNY 264,283,238.89 in Q1 2022[30]. - The total cash outflow from investing activities was CNY 311,844,895.84, an increase of 62.0% compared to CNY 192,607,539.73 in Q1 2022[31]. - The net cash flow from investing activities was -CNY 311,837,895.84, worsening from -CNY 81,691,339.33 in Q1 2022[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,817.47 million, down 2.68% from the end of the previous year[6]. - Total liabilities as of Q1 2023 amounted to ¥197,881,246.94, down from ¥275,298,695.27 in the previous year[26]. - The equity attributable to shareholders increased by 1.72% to CNY 1,619.59 million[6]. - The company's total assets as of March 31, 2023, amounted to RMB 1,817,470,290.79, down from RMB 1,867,488,228.30 at the end of 2022, indicating a decrease of about 2.5%[24]. - Accounts receivable as of March 31, 2023, were RMB 208,133,668.02, down from RMB 238,627,427.15, reflecting a decrease of about 13%[23]. - The company's fixed assets increased to RMB 641,870,702.76 from RMB 581,351,200.34, representing an increase of about 10.4%[24]. - The company’s accounts payable decreased to RMB 89,504,424.06 from RMB 147,606,805.21, a decline of approximately 39%[24]. Strategic Developments - The decline in revenue was attributed to factors such as extensive holidays in January, high sales base from the previous year, and inventory reduction by downstream customers[9]. - The company completed a capital increase of USD 45 million for its wholly-owned subsidiary GD Medical, primarily for the acquisition of core assets from TPI[15]. - GD Medical was renamed Trademark Plastics Inc. following the completion of the asset acquisition[20]. - Research and development expenses for Q1 2023 were ¥16,291,868.49, up from ¥13,734,416.42 in Q1 2022, indicating a focus on innovation[27]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[29].
拱东医疗(605369) - 2023 Q1 - 季度财报